Cooke & Bieler LP raised its holdings in Allergan PLC. (NYSE:AGN) by 25.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 405,201 shares of the company’s stock after acquiring an additional 81,070 shares during the period. Allergan PLC. comprises 1.9% of Cooke & Bieler LP’s holdings, making the stock its 18th biggest holding. Cooke & Bieler LP owned approximately 0.12% of Allergan PLC. worth $98,501,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in AGN. Honeywell International Inc. grew its holdings in shares of Allergan PLC. by 13.6% during the second quarter. Honeywell International Inc. now owns 168,130 shares of the company’s stock worth $40,871,000 after purchasing an additional 20,100 shares during the last quarter. Israel Discount Bank of New York bought a new stake in shares of Allergan PLC. during the first quarter worth about $988,000. Trust Co. of Vermont grew its holdings in shares of Allergan PLC. by 62.8% during the first quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock worth $687,000 after purchasing an additional 1,109 shares during the last quarter. Palladium Partners LLC grew its holdings in shares of Allergan PLC. by 1.7% during the second quarter. Palladium Partners LLC now owns 31,161 shares of the company’s stock worth $7,575,000 after purchasing an additional 523 shares during the last quarter. Finally, Capital Planning Advisors LLC grew its holdings in shares of Allergan PLC. by 79.3% during the first quarter. Capital Planning Advisors LLC now owns 3,674 shares of the company’s stock worth $878,000 after purchasing an additional 1,625 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Shares of Allergan PLC. (NYSE AGN) opened at 233.55 on Monday. The company’s 50-day moving average price is $235.62 and its 200 day moving average price is $237.29. The company has a market cap of $78.08 billion, a P/E ratio of 7.12 and a beta of 1.18. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.35 earnings per share. On average, equities research analysts anticipate that Allergan PLC. will post $16.27 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be paid a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 1.20%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s payout ratio is 9.95%.

COPYRIGHT VIOLATION WARNING: This piece was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/11/allergan-plc-agn-holdings-lifted-by-cooke-bieler-lp.html.

Several analysts have recently weighed in on the company. UBS AG restated a “buy” rating and set a $275.00 price target on shares of Allergan PLC. in a report on Monday, May 15th. Vetr raised Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price objective on the stock in a research note on Monday, June 26th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $280.00 price objective (up from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. Royal Bank Of Canada set a $284.00 price objective on Allergan PLC. and gave the stock a “buy” rating in a research note on Sunday, July 16th. Finally, Deutsche Bank AG reaffirmed a “buy” rating and issued a $273.00 price objective (up from $265.00) on shares of Allergan PLC. in a research note on Monday, July 17th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the company’s stock. Allergan PLC. currently has an average rating of “Buy” and a consensus price target of $275.49.

Allergan PLC. Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.